Is Ranitidine recalled?

100 FDA recalls mention Ranitidine. The most recent are listed below.

Recalls are matched by product description. A recall usually affects specific lots, not every package of Ranitidine.

Class II · Moderate risk Terminated Jan 15, 2020

Ranitidine 300 mg, 30 Tabs bottles, Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 NDC 61919-455-30

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Direct Rx NDC 61919-455-30 D-0017-2021

Class II · Moderate risk Terminated Jan 15, 2020

Ranitidine 150 mg, a) 60 Tabs (NDC 61919-339-60); and b) 90 Tabs (NDC 61919-339-90) bottles, Rx only, Packaged and Distributed…

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Direct Rx NDC 61919-339-60 D-0016-2021

Class II · Moderate risk Terminated Jan 14, 2020

Ranitidine Hydrochloride (powder), USP, Rx only, Spectrum Chemical Mfg Corp., a) 1 gram, b) 5 grams, c) 25 grams, d)100 grams, e)…

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Spectrum Laboratory Products D-0825-2020

Class II · Moderate risk Terminated Jan 10, 2020

ranitidine hydrochloride, USP ,150 mg tablets a) 14-count bottles ( NDC 43063-844-14); b) 30-count bottles (NDC 43063-844-30)…

Reason CGMP Deviations: Received notice from supplier of potential -Nitrosodimethylamine (NDMA) amounts above established levels.

PD-Rx Pharmaceuticals, Inc. NDC 43063-844-14 D-0826-2020

Class II · Moderate risk Terminated Jan 7, 2020

Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 300 mg, Rx Only, a) 14 count bottles (NDC: 68788-6382-1), b) 30 count bottles…

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Preferred Pharmaceuticals, Inc D-0797-2020

Class II · Moderate risk Terminated Jan 7, 2020

Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 150 mg, a) 30 count bottles (NDC: 68788-7388-3), b) 60 count bottles (NDC…

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Preferred Pharmaceuticals, Inc D-0796-2020

Class II · Moderate risk Terminated Jan 7, 2020

Ranitidine Capsules 150 mg, (a) 60 count bottles (NDC 62559-690-60) , (b) 500 count bottles (NDC 62559-690-05), Rx only…

Reason CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Appco Pharma LLC NDC 62559-690-60 D-0649-2020

Class II · Moderate risk Terminated Jan 7, 2020

Ranitidine Capsules 300 mg, 30 count bottles. Rx only, Manufactured by: Appco Pharma LLC, Piscataway, NJ 08854, Distributed by…

Reason CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Appco Pharma LLC NDC 62559-691-30 D-0648-2020

Class II · Moderate risk Terminated Jan 6, 2020

Ranitidine, 150 mg Tablets, a) 7 count, b) 14 count, c) 20 count, d) 30 count, e) 60 count; Rx, Only, H.J. Harkins Company, Inc…

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

H J Harkins Company Inc dba Pharma Pac D-0793-2020

Class II · Moderate risk Terminated Dec 26, 2019

Ranitidine 150 mg tablets, 130 count bottles, NDC 37808-196-04.

Reason CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

AAA Pharmaceutical, Inc. NDC 37808-196-04 D-0646-2020

Class II · Moderate risk Terminated Dec 26, 2019

Ranitidine 150 mg tablets, 24 count bottles, NDC 37808-196-01.

Reason CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

AAA Pharmaceutical, Inc. NDC 37808-196-01 D-0645-2020

Class II · Moderate risk Terminated Dec 20, 2019

Ranitidine Tablets, USP 300 mg a). 15-count bottles (NDC 70934-287-15), b). 90-count bottles (NDC 70934-287-90), Rx Only…

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Denton Pharma, Inc. NDC 70934-287-15 D-0795-2020

Class II · Moderate risk Terminated Dec 20, 2019

Ranitidine Tablets, USP 150 mg , a). 4 count bottle (NDC 70934-017-04), b). 20-count bottle (NDC 70934-017-20), c). 24-count…

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Denton Pharma, Inc. NDC 70934-017-04 D-0794-2020

Class II · Moderate risk Ongoing Dec 17, 2019

Glenmark Ranitidine Tablets USP 150 mg Rx Only 500 Tablets Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bandez, Goa…

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Glenmark Pharmaceuticals Inc., USA NDC 68462-248-05 D-0644-2020

Class II · Moderate risk Ongoing Dec 17, 2019

Glenmark Ranitidine Tablets USP 300 mg Rx Only 250 Tablets Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bandez, Goa…

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Glenmark Pharmaceuticals Inc., USA NDC 68462-249-20 D-0643-2020

Class II · Moderate risk Ongoing Dec 17, 2019

Glenmark Ranitidine Tablets USP 300 mg Rx Only 100 Tablets Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bandez, Goa…

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Glenmark Pharmaceuticals Inc., USA NDC 68462-249-01 D-0642-2020

Class II · Moderate risk Ongoing Dec 17, 2019

Glenmark Ranitidine Tablets USP 300 mg Rx Only 30 Tablets Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bandez, Goa…

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Glenmark Pharmaceuticals Inc., USA NDC 68462-249-30 D-0641-2020

Class II · Moderate risk Ongoing Dec 17, 2019

Glenmark Ranitidine Tablets USP 150 mg Rx Only 100 Tablets Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bandez, Goa…

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Glenmark Pharmaceuticals Inc., USA NDC 68462-248-01 D-0640-2020

Class II · Moderate risk Ongoing Dec 17, 2019

Glenmark Ranitidine Tablets USP 150 mg Rx Only 60 Tablets Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bandez, Goa…

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Glenmark Pharmaceuticals Inc., USA NDC 68462-248-60 D-0639-2020

Class II · Moderate risk Ongoing Dec 13, 2019

RANITIDINE TABLETS, USP 150mg, 10,000-count bag, Country of Origin: INDIA NDC 62207-773-32

Reason CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Granules India Limited NDC 62207-773-32 D-0632-2020

Class II · Moderate risk Terminated Dec 11, 2019

Ranitidine 150 mg tablet Original Supplier's NDC 65162-0253-10 Remedy Repackaged NDC 70518-1714-00

Reason CGMP Deviation; Received notice from supplier of potential -Nitrosodimethylamine (NDMA) amounts above established levels.

RemedyRepack Inc. NDC 65162-0253-10 D-0798-2020

Class II · Moderate risk Terminated Dec 2, 2019

Ranitidine Tablets, USP 150 mg, OTC, a.) 30 count bottle (NDC 68788-7078-03), b.) 60 count bottle (NDC 68788-7078-06), Mfg…

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Preferred Pharmaceuticals, Inc NDC 68788-7078-03 D-0617-2020

Class II · Moderate risk Ongoing Nov 22, 2019

Ranitidine Tablets, USP 300 mg, 250-count bottles, NDC 53746-254-02.

Reason CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Amneal Pharmaceuticals, Inc. NDC 53746-254-02 D-0616-2020

Class II · Moderate risk Ongoing Nov 22, 2019

Ranitidine Tablets, USP 150 mg, 1000-count bottles, NDC 53746-253-10.

Reason CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Amneal Pharmaceuticals, Inc. NDC 53746-253-10 D-0615-2020

Class II · Moderate risk Ongoing Nov 22, 2019

Ranitidine Syrup Oral Solution 15 mg/mL 6. fl. oz. (473 mL), NDC 65162-664-90.

Reason CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Amneal Pharmaceuticals, Inc. NDC 65162-664-90 D-0614-2020

Get an alert if your medication is recalled